Printer Friendly

MAGAININ ANNOUNCES THE ISSUANCE OF THREE PATENTS

 PLYMOUTH MEETING, Pa., July 8 /PRNewswire/ -- Magainin Pharmaceuticals Inc. (NASDAQ: MAGN) today announced the issuance of three patents covering combination products which include the company's anti-infective peptides. The patents describe the enhanced activities of combining the peptides with other known anti-infectives.
 Patent No. 5,208,220 is owned by the company and covers combination products that include certain antibiotics. In laboratory tests, these compositions have demonstrated a broad spectrum of antibacterial activity, including activity against resistant pathogens. Magainin scientists believe that these compositions may have the potential to be used in a variety of treatments including certain infections and burns.
 Patent No. 5,221,664 is owned by the company and covers combination products that include cations, such as the silver cation. Company scientists believe that these compositions may have the potential to be used for the treatment and prevention of eye infections.
 Patent No. 5,217,956 covers combination products that include certain anions, such as fluoride. In laboratory tests, these compositions demonstrated activity against bacteria and fungi and company scientists believe they may have utility as potential oral health care products. The company has an exclusive worldwide patent license agreement for the rights to this patent.
 "The addition of these three patents to our portfolio highlight our strategy of seeking patent protection in the area of host defense and related technologies," said Jay Moorin, president and chief executive officer of Magainin Pharmaceuticals Inc.
 Magainin Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of anti- infectives and anti-cancer products based upon compounds isolated from the host defense systems of animals.
 -0- 7/8/93
 /CONTACT: Jay Moorin, president and CEO of Magainin, 215-941-4020; or Fern Lazar or Kate de Santis of Dewe Rogerson, 212-688-6840, for Magainin/
 (MAGN)


CO: Magainin Pharmaceuticals Inc. ST: Pennsylvania IN: MTC SU:

GK-OS -- NY060 -- 9533 07/08/93 13:18 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 8, 1993
Words:311
Previous Article:HSI MTGE. PASS-THRUS SERIES 1993-D RATED 'AAA/AA' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:THE BUSINESS ROUNDTABLE TO CONSOLIDATE OFFICES; NAMES MAURY SENIOR STAFF EXECUTIVE
Topics:


Related Articles
MAGAININ PHARMACEUTICALS RECEIVES PATENT FOR WOUND HEALING DRUGS
MAGAININ PHARMACEUTICALS ANNOUNCES DISCOVERY OF FIRST STEROID HOST-DEFENSE ANTIBIOTIC
ANERGEN ANNOUNCES ISSUANCE OF KEY PATENT
MAGAININ PHARMACEUTICALS INC. ANNOUNCES MANUFACTURING PROCESS BREAKTHROUGH FOR ITS LEAD DRUG, MSI-78
MAGAININ PHARMACEUTICALS AND SANDOZ ANNOUNCE STRATEGIC ALLIANCE IN CANCER
SCIENTISTS ISOLATE NEW ANTIBIOTICS FROM SHARK
MAGAININ PHARMACEUTICALS RECEIVES PATENT FOR SQUALAMINE
Magainin Pharmaceuticals Buys Out MSI-78 Royalty Stream
Magainin Pharmaceuticals Announces Third Quarter Financial Results
Magainin Announces 1997 Financial Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters